Palbociclib has no clinically relevant effect on the QTc interval in patients with advanced breast cancer


The aim of this study was to assess the potential effects of palbociclib in combination with letrozole on QTc. PALOMA-2, a phase 3, randomized, double-blind, placebo-controlled trial, compared palbociclib plus letrozole with placebo plus letrozole in postmenopausal women with estrogen receptor-positive, human epidermal growth factor receptor 2-negative… (More)
DOI: 10.1097/CAD.0000000000000589

5 Figures and Tables


  • Presentations referencing similar topics